Unredacted COVID Vaccine Contracts Spark Public Deception Accusations

A staggering CHF 1 billion in taxpayer funds is finally under the microscope as the Swiss government’s wall of secrecy crumbles. Following a bruising two-year legal battle, the Federal Office of Public Health (FOPH) has been forced to surrender unredacted vaccine contracts, exposing the raw terms of Switzerland's pandemic response. This isn't just a document release; it is a seismic shift in public accountability. For years, officials shielded these deals from scrutiny, claiming disclosure would jeopardize national interests. However, a federal court has dismantled that defense, ruling that the public's right to know how their money was spent outweighs the convenience of bureaucratic silence. The unredacted files reveal that Switzerland paid between $32 and $40 per Moderna dose—nearly double what the United States negotiated. While the government scrambled for 'priority access,' critics now argue they signed away their leverage, locking the nation into rigid terms that favored pharmaceutical giants over the Swiss treasury. This transparency victory marks the end of an era of 'blind trust' in federal health procurement.

The Swiss state has effectively signed a blank check for pharmaceutical liability, leaving citizens to pick up the tab for potential injuries. The unredacted contracts confirm an alarming reality: Moderna and Novavax are shielded from almost all legal consequences, except in cases of gross negligence or production defects. For every other risk—including rare but serious side effects—the Swiss government, and by extension the taxpayer, assumes full responsibility for damage claims. This 'exceptional' arrangement deviates sharply from standard vaccine procurement, where manufacturers typically bear significant responsibility for their products. Campaign groups like the Action Alliance for a Free Switzerland (ABF) have branded the findings 'shocking,' pointing out that the contracts contain no ironclad obligations for manufacturers to deliver a product with guaranteed efficacy. While the FOPH defends these terms as the necessary price for rapid delivery during a global crisis, the legal analysis suggests a lopsided power dynamic where the state accepted all the risk while the manufacturers pocketed all the profit. The revelation confronts the public with a disturbing question: did the government prioritize speed over safety and fiscal prudence?

More than 18.6 million doses of Covid-19 vaccines have been incinerated, a monumental loss that represents 60% of the total supply purchased by the government. This unprecedented waste is not merely a logistical failure; it is a direct consequence of 'predatory' contract clauses now visible to the public. The unredacted Moderna contract reveals a strict prohibition on the resale or transfer of vaccines outside Swiss territory. This clause effectively handcuffed the government, preventing them from donating or selling surplus stock to nations in need before the doses expired. While Switzerland ordered 61 million doses for a population of just 9 million, only 17 million were ever administered. The resulting 'vaccine graveyard' has cost the country hundreds of millions of francs. Critics argue this over-procurement was reckless, especially as the government continued to push for more doses long after the peak of the pandemic had passed. The contrast is stark: while the FOPH claims it was better to have too many than too few, the sheer scale of the destruction suggests a catastrophic miscalculation in demand forecasting and a failure to negotiate flexible exit strategies.

The fallout from these revelations is surging through the halls of the Federal Palace, as lawmakers demand heads roll for what they describe as a 'public deception.' Swiss People’s Party (SVP) parliamentarian Rémy Wyssman is leading the charge, preparing a series of motions for an upcoming special session of parliament. Wyssman is questioning whether the government violated mandatory procurement laws and intentionally concealed essential contract details from the very body tasked with overseeing them. The accusations are grave: the government is charged with 'misleading the population' by projecting a false sense of safety and necessity while downplaying the experimental nature of the mRNA technology. As the FOPH maintains its defensive stance, arguing its strategy saved lives, the political pressure is mounting for a full independent audit of the pandemic-era administration. This is no longer just a health debate; it is a crisis of confidence in Swiss governance. The implications are clear: the next pandemic will not be managed behind closed doors. The public demand for transparency has been ignited, and the government must now confront the reality that its 'emergency' powers do not grant it immunity from the truth.